Trial Profile
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Taselisib (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab; Trastuzumab emtansine
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 26 Feb 2024 Planned End Date changed from 1 Dec 2022 to 1 May 2024.
- 21 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 14 May 2021 Planned End Date changed from 1 Feb 2021 to 1 Dec 2021.